Long-term study of Tremfya for inflammatory bowel disease
Part of Digestive system clinical trials.
This study follows adults with moderate-to-severe Crohn's disease or ulcerative colitis who are starting treatment with guselkumab (Tremfya). It aims to see how well the medication works and how long the effects last over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with moderate-to-severe Crohn's disease or ulcerative colitis.
- Your doctor has decided to start you on Tremfya as part of your regular care.
- You have not previously taken IL-23 inhibitors like Tremfya, Skyrizi, or Omvoh, but you may have taken Stelara.
- You have had no more than 4 previous advanced treatments for your IBD.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well guselkumab (Tremfya) works for people with moderate-to-severe Crohn's disease or ulcerative colitis in everyday medical practice in Italy. If you qualify, you will receive the treatment normally prescribed by your doctor and help researchers track its real-world effectiveness.
This study tests a drug called guselkumab (Tremfya) for people who have both inflammatory bowel disease (like Crohn's or ulcerative colitis) and joint pain that may be related to arthritis (spondyloarthritis). The goal is to see if this treatment can help with both the gut and joint symptoms.
This study tests whether guselkumab, a newer biologic medication, can better control active Crohn's disease symptoms and inflammation. You'll receive the medication and be monitored closely to see how well it works for you.
This study looks at how well guselkumab (Tremfya) works for people with moderate to severe Crohn's disease or ulcerative colitis when used in everyday medical practice. It collects information from patients who are prescribed this medicine to better understand its long-term effects and safety.
This study tracks how well guselkumab (Tremfya) works in real-life for people with inflammatory bowel disease in Germany. If you are starting this treatment, researchers will watch your progress and ask you to fill out simple surveys about your symptoms.
This study looks at how well guselkumab (Tremfya), a treatment for Crohn's disease and ulcerative colitis, works in everyday patients. Researchers will review medical records to see how long people stay on the medicine and how it helps their symptoms.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.